Evidence map›Paper›PMID 38297082›Full record

ArticleOncogene2024

PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/β-catenin signalling pathway.

Jiangchun Wu, Yong Wu, Siyu Chen, Qinhao Guo, Yang Shao, Chaohua Liu, Kailin Lin, Simin Wang, Jun Zhu, Xiaojun Chen and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Bioinformatic Approach to Identify PotentialInternational journal of molecular sciences · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. The transcription factor FOXQ1 in cancer.Cancer metastasis reviews · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Jiangchun Wu *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Yong Wu *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Siyu Chen *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Qinhao GuoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Yang ShaoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.ORCID 0000-0002-3239-4265
Chaohua LiuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Kailin LinDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Simin WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Jun ZhuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Xiaojun ChenDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Xingzhu JuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Lingfang XiaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Xiaohua WuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. wu.xh@fudan.edu.cn.ORCID 0000-0001-5908-004X
Shanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastasis is an important factor that causes ovarian cancer (OC) to become the most lethal malignancy of the female reproductive system, but its molecular mechanism is not fully understood. In this study, through bioinformatics analysis, as well as analysis of tissue samples and clinicopathological characteristics and prognosis of patients in our centre, it was found that Forkhead box Q1 (FOXQ1) was correlated with metastasis and prognosis of OC. Through cell function experiments and animal experiments, the results show that FOXQ1 can promote the progression of ovarian cancer in vivo and in vitro. Through RNA-seq, chromatin immunoprecipitation sequencing (ChIP-seq), Kyoto Encyclopedia of Genes and Genomes (KEGG), gene set enrichment analysis (GSEA), Western blotting (WB), quantitative real-time polymerase chain reaction (qRT‒PCR), immunohistochemistry (IHC), luciferase assay, and ChIP-PCR, it was demonstrated that FOXQ1 can mediate the WNT/β-catenin pathway by targeting the LAMB promoter region. Through coimmunoprecipitation (Co-IP), mass spectrometry (MS), ubiquitination experiments, and immunofluorescence (IF), the results showed that PARP1 could stabilise FOXQ1 expression via the E3 ubiquitin ligase Hsc70-interacting protein (CHIP). Finally, the whole mechanism pathway was verified by animal drug combination experiments and clinical specimen prognosis analysis. In summary, our results suggest that PARP1 can promote ovarian cancer progression through the LAMB3/WNT/β-catenin pathway by stabilising FOXQ1 expression.

Indexed as

beta CateninOvarian NeoplasmsAnimalsCell Line, TumorCell ProliferationFemaleForkhead Transcription FactorsGene Expression Regulation, NeoplasticHumansPoly (ADP-Ribose) Polymerase-1Wnt Signaling Pathwaybeta CateninForkhead Transcription FactorsFOXQ1 protein, humanPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1

Identifiers

PMID38297082
OpenAlexW4391385558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.